ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,080.50
0.51%
US Tech 100
20,898.40
1.08%
다우존스 지수
44,976.70
0.61%
Bitcoin
96,679.34
0.74%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) 뉴스

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

NASDAQ
17.06
0.44
( 2.65% )
업데이트: 04:23:18
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

SNDX 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
12 11월 2024
SNDX (2.65%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
06 11월 2024
SNDX (2.65%)

Form 8-K - Current report
Edgar (US Regulatory)
06 11월 2024
SNDX (2.65%)

SNDX Discussion

게시물 보기
dinogreeves dinogreeves 3 월 전
Have you looked at TIL on Friday.
👍️0
Monksdream Monksdream 3 월 전
SNDX a buy again
👍️0
dinogreeves dinogreeves 1 년 전
SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
👍️0
dinogreeves dinogreeves 1 년 전
Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
👍️0
dealerschool2006 dealerschool2006 4 년 전
Nice rebound today for $SNDX, beat the street and conference call was successful!!!
👍️0
dealerschool2006 dealerschool2006 4 년 전
SNDX recovering from panic sale!!!
👍️0
dealerschool2006 dealerschool2006 4 년 전
Panic sale for SNDX on positive results...May options wide swings...
👍️0
DaytraderJohn DaytraderJohn 5 년 전
Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
👍️0
ClayTrader ClayTrader 5 년 전
* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX next week is going to be fun
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX holding this baby!
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX keep climbing baby! Going be going up all next week
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX looking awesome from my call at $8.00
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX got us a runner folks!!!
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX Chomp Chomp Chomp!
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX Weeeeeeeeeee
👍️0
BoilerRoom BoilerRoom 5 년 전
Going to run folks.
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX in at $8.00
👍️0
TheFinalCD TheFinalCD 5 년 전
News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
👍️0
whytestocks whytestocks 6 년 전
News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
👍️0
DewDiligence DewDiligence 6 년 전
SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
👍️0
Spartak Spartak 6 년 전
Well, the company is done. What a disaster.
👍️0
DewDiligence DewDiligence 6 년 전
SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.
👍️0
DewDiligence DewDiligence 6 년 전
SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
👍️0
DewDiligence DewDiligence 6 년 전
SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
👍️0
DewDiligence DewDiligence 6 년 전
#msg-143766395
👍️0
DewDiligence DewDiligence 6 년 전
SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
👍️0
DewDiligence DewDiligence 6 년 전
#msg-143642544
👍️0
DewDiligence DewDiligence 6 년 전
SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
👍️0
DewDiligence DewDiligence 6 년 전
SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
👍️0
Spartak Spartak 6 년 전
When does pounding stop? Someone hummers it pretty badly.
👍️0
fsantes fsantes 6 년 전
Ill keep a look out for some then!... I’ve been looking as well. Thank you!
👍️0
DewDiligence DewDiligence 6 년 전
No. I generally post anything that's material.
👍️0
fsantes fsantes 6 년 전
Have you heard any new news on SNDX?
👍️0
fsantes fsantes 6 년 전
I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
👍️0
DewDiligence DewDiligence 6 년 전
SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.
👍️0
fsantes fsantes 6 년 전
Do you know what’s the news that came out about? When I look it’s blank..
👍️0
DewDiligence DewDiligence 7 년 전
SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
👍️0
DewDiligence DewDiligence 7 년 전
SNDX ENCORE-601 update…

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
👍️0
tika1 tika1 7 년 전
After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
👍️0
DewDiligence DewDiligence 7 년 전
Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
👍️0
DewDiligence DewDiligence 7 년 전
SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
👍️0
DewDiligence DewDiligence 7 년 전
The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
👍️0
DewDiligence DewDiligence 7 년 전
SNDX 1Q18 results—cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
👍️0
DewDiligence DewDiligence 7 년 전
SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
👍️0
DewDiligence DewDiligence 7 년 전
Yes—please see my reply in #msg-140012720.
👍️0
tika1 tika1 7 년 전
Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
👍️0
DewDiligence DewDiligence 7 년 전
SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
👍️0

최근 히스토리

NASDAQ
SNDX
Syndax Pharmaceuticals
DBI
I2NF
DAXsubsector Renewable E...
UPBT
NGCBTC
NAGA Coin
DBI
4Q72
DBAG DEMO INAV 21
BIT
UR9Z0W
UniCredit Bank
TG
PR10
Amundi Luxembourg
AQSE
ORA
Ora Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유